Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | ADH1A | P07327 | 1/20 | 0.45 |
| ▸ | ADH4 | P08319 | 1/20 | 0.45 |
| ▸ | ADH7 | P40394 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22404272 | 0.93 | CA2 (0.46) | CA2CA1ADH1BADH1CADH1A | |
| SCHEMBL630853 | 0.88 | — | — | |
| SCHEMBL23762299 | 0.81 | APLNR (0.39) | CA2KMT2AEPHX1ENPP1GBA1 | |
| SCHEMBL22528058 | 0.80 | CA2 (0.43) | CA2CA1CYP2D6ENPP1GBA1 | |
| SCHEMBL17723322 | 0.80 | CA2 (0.43) | CA2CA1CA12ENPP1GBA1 | |
| SCHEMBL22404307 | 0.78 | CA2 (0.46) | CA2ENPP1GBA1 | |
| SCHEMBL16479531 | 0.78 | CA2 (0.42) | CA2CA1KMT2AALDH1A1ENPP1 | |
| Hydrochloric Acid SCHEMBL19583132 | 0.78 | CA2 (0.42) | CA2CA1CA12ENPP1GBA1 | |
| SCHEMBL17723317 | 0.78 | CA2 (0.42) | CA2CA1KMT2AALDH1A1ENPP1 | |
| SCHEMBL16479552 | 0.78 | CA2 (0.42) | CA2CA1KMT2AALDH1A1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116848091-A | Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP 1) and uses thereof | 1CBIO公司 | 2023-10-03 | — | — | CN | disclosed |
| US-9962375-B2 | Methyl-piperidine compounds useful for inhibiting microsomal prostaglandin E2 synthase-1 | ELI LILLY AND COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | ELI LILLY AND COMPANY | 2017-11-16 | — | — | US | disclosed |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| EP-0882023-A1 | HISTAMINE H 3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CA2 466/4885CA1 1123/4885ADH1B 383/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CA2 3200/4885CA1 4432/4885ADH1B 356/4885 |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | PTGS1, PTGES, PTGER1 | CA2 2539/4885CA1 3071/4885ADH1B 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.